Hansa Biopharma AB
- Country
- 🇳🇴Norway
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 168
- Market Cap
- -
Clinical Trials
30
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (27 trials with phase data)• Click on a phase to view related trials
A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group
- Conditions
- Long Term Efficacy and Safety
- Interventions
- Other: Best available treatment administered in the 20-HMedIdeS-19 (PAES) study
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Hansa Biopharma AB
- Target Recruit Count
- 150
- Registration Number
- NCT05937750
- Locations
- 🇮🇹
Azienda Ospedaliera di Padova, Padova, Italy
🇦🇹Medizinische Universitaet Wien, Vienna, Austria
🇨🇿Nephrology Clinic Vídeňská 1958/9, Prague, Czechia
Imlifidase Prior to Kidney Transplant in Highly Sensitised Children
- Conditions
- Kidney Transplantation in Highly Sensitized Patients
- Interventions
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Hansa Biopharma AB
- Target Recruit Count
- 10
- Registration Number
- NCT05753930
- Locations
- 🇫🇮
HUS, Helsinki University Hospital, Helsinki, Finland
🇫🇷Robert Debre University Hospital, Paris, France
🇪🇸Hospital Unviersitari Vall d'Hebron, Nefrología Pediátrica, Barcelona, Spain
Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
- Conditions
- Kidney Transplantation in Highly Sensitized Patients
- Interventions
- Other: Best available treatment administered in the ConfIdeS study
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Hansa Biopharma AB
- Target Recruit Count
- 64
- Registration Number
- NCT05714514
- Locations
- 🇺🇸
University of Chicago, Department of Surgery, Clinical Research Center, Chicago, Illinois, United States
🇺🇸University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
A Study With Imlifidase in Anti-GBM Disease
- Conditions
- Anti-Glomerular Basement Membrane DiseaseGoodpasture SyndromeAnti-Glomerular Basement Membrane Antibody DiseaseGood Pasture Syndrome
- Interventions
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hansa Biopharma AB
- Target Recruit Count
- 50
- Registration Number
- NCT05679401
- Locations
- 🇺🇸
UCLA Medical Center Plaza, Los Angeles, California, United States
🇺🇸John Hopkins Medical Institution, Baltimore, Maryland, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts
- Conditions
- Kidney Transplantation in Highly Sensitized Patients
- Interventions
- Other: Normal Transplantation Routine
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Hansa Biopharma AB
- Target Recruit Count
- 225
- Registration Number
- NCT05369975
- Locations
- 🇦🇹
Medizinische Universitaet Wien, Vienna, Austria
🇧🇪UZ Leuven - Campus Gasthuisberg, Leuven, Belgium
🇨🇿Institut klinicke a experimentalni mediciny (IKEM), Prague, Czechia
- Prev
- 1
- 2
- 3
- 4
- Next